Analysts Set Expectations for GH Research Q1 Earnings

GH Research PLC (NASDAQ:GHRS) – HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for GH Research in a note issued to investors on Thursday, March 12th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.43) EPS and Q4 2027 earnings at ($0.39) EPS.

A number of other research analysts have also weighed in on the stock. Citizens Jmp boosted their target price on shares of GH Research from $39.00 to $42.00 and gave the stock a “market outperform” rating in a research report on Friday, March 6th. Wolfe Research set a $39.00 price objective on GH Research in a research note on Tuesday, January 6th. TD Cowen reissued a “buy” rating on shares of GH Research in a research report on Monday, January 5th. Citigroup restated a “market outperform” rating on shares of GH Research in a research note on Tuesday, January 6th. Finally, Guggenheim set a $34.00 target price on GH Research and gave the company a “buy” rating in a report on Tuesday, March 10th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.13.

GH Research Trading Down 3.7%

NASDAQ:GHRS opened at $14.95 on Monday. The firm has a market capitalization of $927.35 million, a PE ratio of -18.69 and a beta of 1.00. GH Research has a 1 year low of $7.98 and a 1 year high of $19.51. The firm’s fifty day simple moving average is $15.72 and its 200 day simple moving average is $14.34.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06.

Institutional Trading of GH Research

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC raised its position in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after buying an additional 822 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research during the fourth quarter worth about $38,000. Osaic Holdings Inc. grew its position in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. bought a new position in GH Research during the second quarter valued at about $79,000. Finally, Virtus Investment Advisers LLC bought a new position in GH Research during the second quarter valued at about $89,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.